Introduction
In the new joint European Society of Cardiology (ESC)/European Association of Cardio-Thoracic Surgery (EACTS) Guidelines (2017) for the management of valvular heart disease, indications for transcatheter aortic valve implantation (TAVI) have been markedly expanded. 1 Based on data from large randomized controlled trials, TAVI has been shown to be a minimally invasive, safe, and effective treatment option. During TAVI, large-bore catheters and stiff guidewires are used to treat often fragile patients with severe calcific aortic valve stenosis. Earlier studies have reported that life-threatening complications during TAVI exceed the spectrum and severity of those observed during percutaneous coronary interventions (PCI). 2, 3 In the previous ESC/EACTS Guidelines (2012) , it has been estimated that approximately 1-2% of TAVI patients require emergent cardiac surgery (ECS) for life-threatening complications. 4 Rapid technological development with refinements of TAVI devices, better pre-procedural imaging, and increasing operators' experience have reduced TAVI-related complications 5 and, importantly, the risk of severe complications has declined in recent years. 6 Nevertheless, catastrophic complications such as annular rupture or aortic dissection ultimately requiring ECS continue to occur. 3, 7, 8 Contemporary data on incidence, short-and longerterm outcomes, and risk factors for adverse outcomes of TAVI patients undergoing ECS are not available.
It was the aim of the present European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI) to study the patient profiles, incidence, and outcomes of ECS during TAVI in a contemporary real-world multicentre setting with additional focus on postdischarge outcomes.
Methods

Registry design
The European Registry on Emergent Cardiac Surgery during TAVI (EuRECS-TAVI) is an investigator-initiated independent multicentre observational registry conducted by a group of investigators from Europe, Israel, and New Zealand. The registry was restricted to transfemoral (TF)-TAVI procedures only. In a first survey part, the participating sites were asked for the annual number of TF-TAVI procedures performed in the 2013-16 period and-if any-the annual number of patients needing ECS requiring full sternotomy. Next, details were obtained from those TF-TAVI patients that underwent ECS using dedicated case report forms-thereby collecting data about the onset of complication(s), baseline patient and procedural characteristics, the immediate post-operative course, and longer-term clinical outcomes.
Definitions
Emergent cardiac surgery was defined according to the Valve Academic Research Consortium-2 (VARC-2) Consensus document as any conversion to open sternotomy during the TAVI procedure secondary to Incidence and outcomes of emergent cardiac surgery during TAVI procedure-related complications. 9 All cardiac surgical procedures performed beyond the first 48 h after TAVI were excluded. Semi-elective ECS was defined as any surgery that was not performed immediately during the TAVI procedure but with some time delay. Immediate procedural mortality was defined according to VARC-2 as death <72 h after TAVI. In-hospital mortality was defined as death occurring after TAVI during the same hospital stay. Balloon-expandable transcatheter heart valves (THV) included the Sapien XT and Sapien S3 valve (Edwards Lifesciences, Irvine, CA, USA). 
Results
Seventy-nine centres performing a total of 27 760 TF-TAVI procedures between 2013 and 2016 participated in the registry. During the study period, annual TF-TAVI numbers increased from 4297 in 2013 to 9601 in 2016. Rates of ECS at different centres varied between 0% and 6.7%; 25 centres performing 3821 TF-TAVI procedures (13.3% of the total TAVR volume) reported no case in whom ECS was used. Overall, 212 (0.76%) of the 27 760 patients underwent ECS secondary to TAVI complications. In an additional 60 TAVI patients, ECS was considered during the procedure but finally not performed (worst-case calculation of ECS incidence: 0.98%). The proportion of patients undergoing ECS decreased from 1.07% in 2013 to 0.70% in 2014; this ECS rate remained stable at 0.68% and 0.73% for 2015 and 2016, respectively ( Figure 1) .
Patients undergoing ECS were 82.4 ± 6.3 years of age and predominantly females (67.5%). Mean logistic EuroSCORE was 17.1% and mean STS risk score 5.8% (Table 1) . Forty-nine patients (23%) were at high surgical risk, as defined by a logistic EuroSCORE > 20%. The distribution of different valve types used in those TF-TAVI patients with need for ECS was similar to the distribution of valve types used in the total TF-TAVI population (see Supplementary material online, Figure S1 ). Emergent cardiac surgery was performed for different TAVI complications with left ventricular (LV) perforation by the guidewire (28.3%) and annular rupture (21.2%) accounting for almost half of ECS cases. THV embolization/migration (12.7%), aortic dissection (11.8%), and other complications such as pacing lead perforation, coronary obstruction, pericardial tamponade, or LV perforation by the delivery system were less frequent causes for ECS ( Figure 2A ). Temporal trends of the different types of complications necessitating ECS showed a stable incidence for most complications, except for annular rupture which significantly decreased over time (P = 0.026; Figure 2B ).
Most complications (>90%) occurred and manifested acutely during the TAVI procedure; only a minority (n = 7, 3.3%) of complications leading to ECS became evident >24 h after the procedure. Cardiac surgery was performed acutely in 168 cases (79.2%) and semi-electively in 44 other cases (20.8%). This surgery was most often performed on the TAVI table in the (hybrid) catheterization lab (n = 129, 61.1%) vs. 82 patients (38.9%) that were transferred to a surgical operating room. No patient was transferred to another hospital for ECS. In 42% of cases, the THV was explanted and replaced by a new bioprosthesis.
Immediate procedural mortality (<72 h) of ECS according to VARC-2 definition was 34.6% (73/211 patients). In-hospital mortality was 46% (97/211 patients). Death usually occurred early after ECS (5.5 ± 14.4 days, median 0 days) with half of fatalities (51/97, 52.0%) occurring on the day of surgery. One year survival 
of the 114 patients surviving the in-hospital period was 40.4 ± 4.9% ( Figure 3A) . In-hospital mortality rates were highest in case of ECS for annular rupture (62.2%) followed by coronary obstruction (54.5%), aortic dissection (52.0%), and LV guidewire perforation (50.8%) ( Figure 3B) .
Seventeen TAVI patients undergoing ECS had previous cardiac surgery. These patients were younger (79.2 ± 6.3 vs. 82.3 ± 5.9 years, P = 0.019) and had higher predicted mortality risk (logistic EuroSCORE 26.7 ± 15.9% vs. 16 .2 ± 8.8%, P < 0.001) as compared to those patients without previous cardiac surgery. However, in-hospital mortality was similar between the two groups (41.2% in patients with previous cardiac surgery vs. 46 .1% in those without, P = 0.802).
Univariate logistic regression analysis showed that age > 85 years, use of balloon-expandable THV, annular rupture, and acute ECS were significantly associated with in-hospital mortality in case of ECS. None of the seven patients with complications manifesting beyond 24 h died after ECS. Multivariable regression analysis revealed age > 85 years, annular rupture, and immediate ECS to be independent predictors of in-hospital mortality in case of ECS ( Table 2) . The majority of TF-TAVI patients (n = 22/26, 84.6%) needing ECS without any of these three factors were discharged alive (see Supplementary 
material online, Figure S2 ). In contrast, TF-TAVI patients with all these three factors had an in-hospital mortality of 75% (n = 9/12).
Different transcatheter heart valve types and their risk for complications leading to emergent cardiac surgery Left ventricular perforation by the guidewire was reported in a similar range for all three different THV types. Annular rupture occurred more frequently with balloon-expandable THV as compared to selfexpanding or mechanically-expandable THV (32.0% vs. 15 .4% vs. 0%, P < 0.001). Consequently, in case of ECS following TAVI with a balloon-expandable THV, complications more often manifested acutely, prompting more acute ECS and resulting in a higher in-hospital mortality. Aortic dissection occurred more frequently with mechanically expandable THV (Tables 3 and 4) .
Low-volume vs. high-volume centres
Low-volume hospitals performed a median of 28 TF-TAVI procedures per year (range 3-49) while high-volume centres performed a median of 116 TF-TAVIs annually (range 50-475). There was no difference between the two groups with regards to incidence of ECS Figure S3 ).
Discussion
This contemporary, observational, multicentre registry comprises the largest series of patients requiring ECS during TF-TAVI (n = 212). Based on data of 27 760 TF-TAVI procedures, it can be stated that the incidence of severe procedural complications requiring ECS varied between sites, but was overall low at 0.76% (worst-case calculation also including patients in whom ECS was considered but not performed: 0.98%). Annual numbers of TF-TAVI procedures increasedly markedly over the past 3 years. The need for ECS remained stable. Complications necessitating ECS typically manifested acutely during the TF-TAVI procedure and prompted immediate open heart surgery in 80% of patients. One third of patients died within 72 h of ECS and almost half of the patients during the index hospitalization.
Patients with annular rupture were at the highest risk with an inhospital mortality rate of 62%. At 1 year of follow-up, only 40% of patients surviving the in-hospital period were still alive.
In the early phase of this registry (2013), the risk of ECS was 1.07% and very comparable to that from previous analyses reporting ECS rates between 1.1% and 1.2%. 10, 11 The data from this contemporary study suggest that rates of ECS may have declined, from 1.07% in 2013 to a stable rate of 0.7% for the period 2014-16. This is also consistent with a previous report from the German Quality Assurance Registry on Aortic Valve Replacement (AQUA) showing a similar decline in the risk of intra-procedural complications as well as in the need for ECS during TAVI from 1.2% in 2012 to 0.6% in 2014. 6 Supported by strong evidence from randomized trials, the 2017 ESC/EACTS Guidelines have expanded the indications for TAVIwhenever anatomically feasible-to elderly patients >75 years who are not low-risk for surgery. 1 Clinical use of TAVI has significantly increased worldwide since the early days and even since the start of this registry. In our analysis, annual numbers of TF-TAVI have more than doubled between 2013 and 2016, a trend similar to that observed in Germany and the USA. 12, 13 This increase in operators'
experience, along with better TAVI devices and improvements in pre-procedural imaging, may have accounted for the lower incidence of severe complications needing ECS observed in recent years. In addition, also the lower risk profile of the more recently treated patients may have contributed to this lower incidence of ECS during TF-TAVI. 6, 14 In earlier studies, valve embolization/migration was the leading cause for ECS. 8 In the present analysis, this complication was responsible for only 10-15% of all TF-TAVI cases ending up with ECS. This finding can most likely be ascribed to the use of newer-generation and often repositionable THVs in this contemporary study as well as to enhanced operators' experience nowadays. It was somewhat surprising to find that LV guidewire perforation was in fact the leading cause for ECS. Almost one-third of the patients underwent ECS for LV perforation by the guidewire, and the incidence of this complication remained stable over the past 3 years. The recent availability of dedicated pre-shaped TAVI guidewires will hopefully result in a lower incidence of this specific complication and thus may decrease the need for ECS in the future even further. 15 Annular rupture was found to be the second leading cause for ECS. Fortunately, we noted a downward trend for annular rupture as a cause for ECS in this study from 2013 to 2016. This may, in part, be attributed to more routine use of multidetector computed tomography (CT) for aortic root assessment and, hence, more accurate THV sizing in current practice and identification of patients with high-risk anatomy for serious complications. Severe calcifications extending into the LV outflow tract have been identified as a risk factor for annular rupture. 16, 17 In such patients, the risk for annular rupture may be mitigated by cautious oversizing and using self-expanding THVs instead of balloonexpandable THVs. Computed tomography imaging affords for more accurate THV sizing, thereby avoiding the use of oversized balloons and/or valves. 18 Finally, there is an increasing trend towards less predilatation of the native aortic valve and-if performed at all-more use of undersized balloons, which may further contribute to a lower incidence of annular rupture. 19 Our data indicated that specific complications may be more frequent with some type of THV devices. Annular rupture was more frequently observed in patients treated with balloon-expandable THVs, whereas aortic dissection was more commonly seen when using mechanically expandable THVs. A THV choice tailored to the risk profile of the patient may further decrease the number of severe As reported earlier, mortality among TF-TAVI patients needing ECS was high, mainly reflecting the seriousness of the complication that mandated emergent ECS. 20 Nevertheless, more than half of the patients with serious TAVI complications proceeding to ECS could be salvaged by surgery. The observed in-hospital mortality of 46% was almost identical to previous studies reporting 30 days of mortality rates of 46% to 52%. 8, 10, 11 Mortality after ECS was higher among patients aged > 85 years and those with annular rupture and needing immediate ECS; this finding may help to identify those patients in whom even ECS may not be helpful. In accordance to previous reports, we noted differences in in-hospital mortality rates depending on the underlying complication causing ECS. Patients with annular rupture had the highest mortality of 62%. This is in line with data from the European SOURCE registry and the German TAVI registry reporting 30 days of mortality rates-in smaller number of patients-of 57% and 67%, respectively. 8, 10 Other complications such as coronary obstruction, aortic dissection, and LV guidewire perforation were also associated with in-hospital mortality rates exceeding 50%. A better understanding and preparation to manage these kinds of complications 21 may have the potential to further decrease mortality in these patients.
Clinical implications
Our analysis has several potential clinical implications. Severe complications requiring ECS during TAVI are rare, occurring in <1% of patients in contemporary TF-TAVI practice. Although half of the patients with such complications proceeding to ECS were salvaged acutely, mid-term outcomes were bleak. Prevention of complications needing ECS remains the most important strategy for improving outcomes of TAVI patients. Better pre-procedural imaging to identify patients at higher risk of specific complications and subsequent individual tailoring of the TAVI procedure may help to reduce fatal complications. The unexpected high rate of LV guidewire perforations merits evaluation of strategies to reduce this, e.g. the use of dedicated stiff guidewires with pre-shaped curves. Finally, vigilance for complications may allow earlier identification and result in a better management of these complications. Thus, our data identifies several opportunities to design and target strategies to decrease the incidence of ECS as well as improve its outcomes in the future.
Limitations
Despite being the largest series of TF-TAVI patients needing ECS, our registry is mainly limited by the (still) modest number of ECS patients as well as it's observational, retrospective design. Specifically, given the small number of cases and even smaller number of events, we lacked robust statistical power to detect some meaningful differences. All data were self-reported by the centres without on-site data verification. This study only focused on mortality, other important outcomes such as quality of life and functional status were not investigated.
Conclusion
Emergent cardiac surgery during TAVI is a rare event that is needed in <1% of TF-TAVI patients. Complications necessitating ECS mainly comprised of LV guidewire perforation, annular rupture, valve embolization/migration, and aortic dissection. Despite the high-risk profile of the patients, more than half of the patients could be salvaged acutely by ECS. However, mortality varied with the type of complications with highest mortality seen in those patients with annular rupture. Overall, less than 25% of TF-TAVI patients undergoing ECS survived at 1 year. Thus, prevention of severe complications should be the main focus in order to further improve overall survival in TF-TAVI patients in the future.
